Cargando…
PD-L1 is an activation-independent marker of brown adipocytes
Programmed death ligand 1 (PD-L1) is expressed on a number of immune and cancer cells, where it can downregulate antitumor immune responses. Its expression has been linked to metabolic changes in these cells. Here we develop a radiolabeled camelid single-domain antibody (anti-PD-L1 VHH) to track PD-...
Autores principales: | Ingram, Jessica R., Dougan, Michael, Rashidian, Mohammad, Knoll, Marko, Keliher, Edmund J., Garrett, Sarah, Garforth, Scott, Blomberg, Olga S., Espinosa, Camilo, Bhan, Atul, Almo, Steven C., Weissleder, Ralph, Lodish, Harvey, Dougan, Stephanie K., Ploegh, Hidde L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608754/ https://www.ncbi.nlm.nih.gov/pubmed/28935898 http://dx.doi.org/10.1038/s41467-017-00799-8 |
Ejemplares similares
-
Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018) -
Use of (18)F-2-Fluorodeoxyglucose
to Label Antibody Fragments for Immuno-Positron Emission Tomography
of Pancreatic Cancer
por: Rashidian, Mohammad, et al.
Publicado: (2015) -
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
por: Rashidian, Mohammad, et al.
Publicado: (2017) -
Noninvasive imaging of immune responses
por: Rashidian, Mohammad, et al.
Publicado: (2015) -
Inhibition of non-homologous end joining increases the efficiency of CRISPR/Cas9-mediated precise [TM: inserted] genome editing
por: Maruyama, Takeshi, et al.
Publicado: (2015)